Nevro wins CE mark for HFX iQ spinal cord stim for pain relief

Nevro (NYSE:NVRO) announced today that it received CE mark in Europe for its HFX iQ spinal cord stimulation (SCS) system.

HFX iQ utilizes AI, high-frequency (10 kHz) therapy and ongoing cloud insights to deliver personalized pain relief. It features an implantable pulse generator (IPG), trial stimulator and application. It includes a new, Bluetooth-enabled IPG, that offers upgrades and direct connection to the HFX app. Each patient can input assessments into their smartphone and receive adjustments in real-time.

The system utilizes the HFX algorithm to select programs most likely to provide pain relief for patients. Nevro built this on more than 20 million data points and 80,000 implanted patients. The system combines clinical inputs like pain relief and pain score to provide an individualized program setting.

Sign up for Blog Updates